Deferasirox is a powerful NF-κb inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

Haematologica

Volumn 95, Issue 8, 2010, Pages 1308-1316

  Messa, Emanuela ^a   Carturan, Sonia ^a   Maffè, Chiara ^a   Pautasso, Marisa ^a   Bracco, Enrico ^a   Roetto, Antonella ^a   Messa, Francesca ^a   Arruga, Francesca ^a   Defilippi, Ilaria ^a   Rosso, Valentina ^a   Zanone, Chiara ^a   Rotolo, Antonia ^a   Greco, Elisabetta ^a   Pellegrino, Rosa M ^a   Alberti, Daniele ^b   Saglio, Giuseppe ^a   Cilloni, Daniela ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Novartis Pharma   (Italy)

Author keywords

Iron chelation therapy; Myelodysplastic symdrome; Nuclear factor b

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; ETOPOSIDE; HEMOGLOBIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRON; QUINOLINOL DERIVATIVE; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CELL STRAIN K 562; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; INCUBATION TIME; INHIBITION KINETICS; IRON CHELATION; LEUKEMIA; MALE; MYELODYSPLASTIC SYNDROME; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; APOPTOSIS; BENZOIC ACIDS; BLOTTING, WESTERN; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IRON; IRON CHELATING AGENTS; K562 CELLS; LEUKEMIA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NF-KAPPA B; PROTEIN BINDING; REACTIVE OXYGEN SPECIES; TRIAZOLES;

EID: 77956049342     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.016824     Document Type: Article

References (47)

1. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica. 1998; 83(1):71-86.
2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-88.
3. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005; 23(30):7594-603.
4. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-10.
5. Leitch HA. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res. 2007;31S3:S7-9.
6. Gattermann N. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk Res. 2007;31S3:S10-5.
7. Rose C, Brechignac S, Vassilief D, Beyne-Rauzy O, Stamatoullas A, Larbaa D, et al. Positive Impact of Iron Chelation Therapy (CT) on Survival in Regularly Transfused MDS Patients. A Prospective Analysis by the GFM. Blood. 2007;110:(abstract [249]).
8. Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80:168-76.
9. Pullarkat V. Objectives of iron chelation therapy in myelodysplastyc syndromes: more than meets the eye? Blood. 2009; 114(26):5251-5.
10. Tefferi A, Stone RM. Iron chelation therapy in myelodysplastic syndrome - Cui bono? Leukemia. 2009;23(8):1373.
11. Steensma DP. Myelodysplasia paranoia: iron as the new radon. Leuk Res. 2009; 33(9):1158-63.
12. List AF, Baer MR, Steensma D, Raza A, Esposito J, Virkus J, et al. Iron chelation with deferasirox (Exjade) improves iron burden in patients with myelodysplastic syndromes (MDS). Blood. 2008;112: (abstract[634]).
13. Di Tucci AA, Murru R, Alberti D, Rabault B, Deplano S, Angelucci E. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy wih deferasirox (Exjade, ICL670). Eur J Haematol. 2007;78(6):540-2.
14. Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol. 2008;120(2):70-4.
15. Marsh JH, Hundert M, Schulman P. Deferoxamine-induced restoration of haematopoiesis in myelofibrosis secondary to myelodysplasia. Br J Haematol 1990; 76(1):148-9.
16. Jensen PD, Jensen IM, Ellegaard J. Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol. 1992;80(1):121-4.
17. Jensen PD, Heickendorff L, Pedersen B. The effet of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996;94(2):288-99.
18. Smeets ME, Vreugdenhil G, Holdrinet RS. Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis. Am J Hematol. 1996;51(3): 243-4.
19. Aggarwal BB. Nuclear factor-kB: the enemy within. Cancer Cell. 2004;6(3):203-8.
20. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225-60.
21. Karin M, Cao Y, Greten FR, Li ZW. NFkappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002; 2(4):301-10.
22. Perkins ND. NF-kappaB: tumor promoter or suppressor? Trends Cell Biol. 2004; 14(2):64-9.
23. Guzman M, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98(8): 2301-7.
24. Braun T, Carvalho G, Coquelle A, Vozenin MC, Lepelley P, Kiladjian JJ, et al. NFkappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood. 2006;107(3):1156-65.
25. Hayden MS, Ghosh S. Shared principles in NF-kappaB signalling. Cell. 2008;132(3): 344-62.
26. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the YNF-induced NFkappaB signal. Immunity. 1998;8(3):297-303.
27. Zhang SQ, Kovalenko A, Cantarella G, Wallach D. Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity. 2000; 12(3):301-11.
28. Bubici C, Papa S, Pham CG, Zazzeroni F, Franzoso G. NF-kappaB and JNK: an intricate affair. Cell Cycle. 2004;3(12):1524-9.
29. Bubici C, Papa S, Dean K, Franzoso D. Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene. 2006;25(51):6731-48.
30. Papa S, Bubici C, Pham CG, Zazzeroni F, Franzoso G. NF-kappaB meets ROS: an "iron-ic" encounter. Cell Death Differ. 2005;12(10):1259-62.
31. Wang Y, Huang X, Cang H, Gao F, Yamamoto T, Osaki T, et al. The endogenous reactive oxygen species promote NFkappaB activation by targeting on activation of NF-kappaB-inducing kinase in oral squamous carcinoma cells. Free Radic Res. 2007;41(9):963-71.
32. Lluis J, Buricchi F, Chiarugi P, Morales A, Fernandez-Checa JC. Dual role of mithocondrial reactive oxygen species in hypoxia signalling: activation of nuclear factor-{kappa}B via c-SRC and oxidant-dependent cell death. Cancer Res. 2007;67(15): 7368-77.
33. Jimenez LA, Thompson J, Brown DA, Rahman I, Antonicelli F, Duffin R, et al. Activation of NF-kappaB by PM(10) occurs via an iron-mediated mechanism in the absence of IkappaB degradation. Toxicol Appl Pharmacol. 2000;166(2):101-10.
34. Xiong S, She H, Tsukamoto H. Signaling role of iron in NF-kappa B activation in hepatic macrophages. Comp Hepatol. 2004;3 (Suppl 1):S36.
35. Tsukamoto H. Iron regulation of hepatic macrophage TNFalpha expression. Free Radic Biol Med. 2002;32(4):309-13.
36. Kim KM, Kim PK, Kwon YG, Bai SK, Nam WD, Kim YM. Regulation of apoptosis by nitrosative stress. J Biochem Mol Biol. 2002;35(1):127-33.
37. Omidvar N, Kogan S, Beurlet S, le Pogam C, Janin A, West R, et al. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Cancer Res. 2007;67(24): 11657-67.
38. Rassool FV, Gaymes TJ, Omidvar N, Brady N, Beurlet S, Pla M, et al. Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? Cancer Res. 2007;67(18):8762-71.
39. Koptyra M, Falinski R, Nowicki, Stoklosa T, Majsterek I, Nieborowska-Skorska M, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance Blood. 2006; 108(1):319-27.
40. Ghoti H, Amer J, Winder A, Rachmilewitz E, Fibach E. Oxidative stress in red blood cells, platelets and polymorphonuclear eukocytes from patients with myelodysplastic syndrome. Eur J Haematol. 2007;79(6):463-7.
41. Shvartsman M, Kikkeri R, Shanzer A, Cabantchik ZI. Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications. Am J Physiol Cell Physiol. 2007;293(4):1383-94.
42. Cilloni D, Messa F, Arruga F, Defilippi I, Morotti A, Messa E, et al. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia. 2006;20(1):61-7.
43. Ruddell RG, Hoang-Le D, Barwood JM, Rutherford PS, Piva TJ, Watters DJ, et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology. 2009;49(3):887-900.
44. Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Martinelli G, et al. PKR is activated in MDS patients and its subcellular localization depends on disease severity. Leukemia. 2008;22(12):2267-9.
45. Camaschella C, Campanella A, De Falco L, Boschetto L, Merlini R, Silvestri L, et al. The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood. 2007;110(4): 1353-8.
46. Frelin C, Imbert V, Griessinger E, Peyron AC, Rochet N, Philip P, et al. Targeting NFkappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood. 2005;105(2):804-11.
47. Cilloni D, Messa F, Rosso V, Arruga F, Defilippi I, Carturan S, et al. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations. Leukemia. 2008;22(6):1234-40.